Merck & Co. Inc. (MRK)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priori...

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...

Tech stocks lagged after a very strong first half of the year, while healthcare led the way.

My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performi...

Dividend Yield Theory identifies Merck & Co., Inc. as undervalued, with a 4.09% yield well above its historical mean, suggesting strong total return potential. Despite Keytruda's looming patent expira...

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29.

Merck: Don't Let Today's Bargain Opportunity Pass You By

Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant s...